JP2024544698A5 - - Google Patents
Info
- Publication number
- JP2024544698A5 JP2024544698A5 JP2024534196A JP2024534196A JP2024544698A5 JP 2024544698 A5 JP2024544698 A5 JP 2024544698A5 JP 2024534196 A JP2024534196 A JP 2024534196A JP 2024534196 A JP2024534196 A JP 2024534196A JP 2024544698 A5 JP2024544698 A5 JP 2024544698A5
- Authority
- JP
- Japan
- Prior art keywords
- hyperglycemia
- salt according
- disorder characterized
- salt
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2117828.0A GB2613616A (en) | 2021-12-09 | 2021-12-09 | New formulations |
| GB2117828.0 | 2021-12-09 | ||
| PCT/EP2022/085133 WO2023105035A1 (en) | 2021-12-09 | 2022-12-09 | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024544698A JP2024544698A (ja) | 2024-12-03 |
| JP2024544698A5 true JP2024544698A5 (https=) | 2025-12-05 |
Family
ID=80079964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534196A Pending JP2024544698A (ja) | 2021-12-09 | 2022-12-09 | 高血糖症及び２型糖尿病の治療のための（ｒ）－２－（ｔｅｒｔ－ブチルアミノ）－１－（５－フルオロピリジン－３－イル）－エタン－１－オールヘミ酒石酸塩の結晶形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250042856A1 (https=) |
| EP (1) | EP4444699A1 (https=) |
| JP (1) | JP2024544698A (https=) |
| KR (1) | KR20240116482A (https=) |
| CN (1) | CN118525004A (https=) |
| AU (1) | AU2022405700A1 (https=) |
| CA (1) | CA3241501A1 (https=) |
| GB (1) | GB2613616A (https=) |
| IL (1) | IL313292A (https=) |
| MX (1) | MX2024006960A (https=) |
| WO (1) | WO2023105035A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202303229D0 (en) * | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| JP7682097B2 (ja) * | 2019-03-27 | 2025-05-23 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニスト及びそれを使用する方法 |
-
2021
- 2021-12-09 GB GB2117828.0A patent/GB2613616A/en active Pending
-
2022
- 2022-12-09 KR KR1020247020161A patent/KR20240116482A/ko active Pending
- 2022-12-09 JP JP2024534196A patent/JP2024544698A/ja active Pending
- 2022-12-09 MX MX2024006960A patent/MX2024006960A/es unknown
- 2022-12-09 CA CA3241501A patent/CA3241501A1/en active Pending
- 2022-12-09 US US18/717,134 patent/US20250042856A1/en active Pending
- 2022-12-09 AU AU2022405700A patent/AU2022405700A1/en active Pending
- 2022-12-09 IL IL313292A patent/IL313292A/en unknown
- 2022-12-09 EP EP22835607.7A patent/EP4444699A1/en active Pending
- 2022-12-09 CN CN202280081693.4A patent/CN118525004A/zh active Pending
- 2022-12-09 WO PCT/EP2022/085133 patent/WO2023105035A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024544698A5 (https=) | ||
| JP2023531311A5 (https=) | ||
| JP2024001048A5 (https=) | ||
| TWI331916B (en) | Tuberculosis treatment | |
| JPS584752A (ja) | カルボキシアミド誘導体及びその製造法 | |
| JP5305421B2 (ja) | ジアミン誘導体の製造方法 | |
| JP2014503574A5 (https=) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2022533971A5 (https=) | ||
| JP2015505301A5 (https=) | ||
| CN1612863A (zh) | 氘代的取代的吡唑基－苯磺酰胺以及包含该化合物的药物组合物 | |
| US11517565B2 (en) | Bis-amines, compositions, and uses related to CXCR4 inhibition | |
| TW201427977A (zh) | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體致效劑活性之化合物 | |
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| JP2018529690A5 (https=) | ||
| JP2022525795A5 (https=) | ||
| JP2024546138A5 (https=) | ||
| JP2023530785A5 (https=) | ||
| JP2006511506A5 (https=) | ||
| JP2020534266A5 (https=) | ||
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| JP2009541455A5 (https=) | ||
| WO2005023766A1 (en) | Salt of atorvastatin with metformin | |
| CN1642926A (zh) | 结晶帕瑞考昔钠 | |
| JP3853389B2 (ja) | 新規の３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１］ノナン−化合物、その製法及び抗不整脈剤 |